Viridian Therapeutics, Inc./DE Costs and Expenses
Viridian Therapeutics, Inc./DE (VRDN) reported Costs and Expenses of $15.85 million for the 12-month period ending 2016-12-31, per its 10-K filed 2017-03-24.
Discontinued › Expense Statement › Operating Expenses
us-gaap:CostsAndExpenses · last filed 2017-03-24
- Viridian Therapeutics, Inc./DE costs and expenses for the quarter ending 2016-12-31 was $6.23M, a 72.26% increase year-over-year.
- Viridian Therapeutics, Inc./DE costs and expenses for the quarter ending 2016-09-30 was $2.71M, a 25.46% decline year-over-year.
- Viridian Therapeutics, Inc./DE costs and expenses for the quarter ending 2015-12-31 was $3.62M.
- Viridian Therapeutics, Inc./DE costs and expenses for the quarter ending 2015-09-30 was $3.63M.
- Viridian Therapeutics, Inc./DE costs and expenses for fiscal 2016 was $15.85M, a 15.45% increase from fiscal 2015.
- Viridian Therapeutics, Inc./DE costs and expenses for fiscal 2015 was $13.72M.
| Period end | Costs and Expenses 3 month | Costs and Expenses 6 month | Costs and Expenses 9 month | Costs and Expenses 12 month |
|---|---|---|---|---|
| 2016-12-31 | $6.23M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-24 | $8.93M derived: sum of 2 quarters · filed 2017-03-24 | $15.85M 10-K · filed 2017-03-24 | |
| 2016-09-30 | $2.71M 10-Q · filed 2016-10-26 | $9.62M 10-Q · filed 2016-10-26 | ||
| 2015-12-31 | $3.62M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-24 | $7.25M derived: sum of 2 quarters · filed 2017-03-24 | $13.72M 10-K · filed 2017-03-24 | |
| 2015-09-30 | $3.63M 10-Q · filed 2016-10-26 | $10.11M 10-Q · filed 2016-10-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |